Cisplatin Plus Standard-of-Care Regimen Reduced Tumors in Advanced Pancreatic Cancer

Share this content:
Diagnoses of pancreatic cancer typically occur at later stages of the disease, hindering therapy.
Diagnoses of pancreatic cancer typically occur at later stages of the disease, hindering therapy.

The addition of cisplatin to standard-of-care gemcitabine/nab-paclitaxel drug treatment improved shrinkage of tumors in patients with metastatic pancreatic cancer.

Results from this phase 1b/2 clinical trial, presented at the 2017 Gastrointestinal Cancers Symposium, indicated that 3 treatment cycles decreased tumor markers and resulted in significant tumor shrinkage in just 9 weeks.

"After treatment, 2 patients had no evidence of disease and are alive over 3 years after starting this regimen. This is very rare with traditional chemotherapy," said Gayle Jameson, nurse practitioner and principal investigator of the clinical trial.

Twenty-four patients were evaluated. Median overall survival (OS) was 16.5 months, which exceeds the historical median OS of 6 to 12 months with standard chemotherapy.

Nearly three-quarters of patients (71%) experienced a reduction in tumor size of at least 30%. Of these 17 patients, 2 experienced complete response.

This trial began in 2013. Stand Up To Cancer, Mattress Firm, the Arizona Diamondbacks, and the Seena Magowitz Foundation funded this study.

Diagnoses of pancreatic cancer frequently occur at later stages of the disease, making it hard to treat. Only approximately one-quarter of patients with the disease survive more than 1 year, and less than 10% survive longer than 5 years.


1. TGen-HonorHealth Research Institute clinical trial reports high rate of tumor shrinkage among patients with advanced pancreatic cancer [press release]. Scottsdale, AZ; April 25, 2017. Accessed May 9, 2017.

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs